AKT1 and lung cancer: In non‐small cell lung cancer, METTL3 upregulation causes elevated m6A modification and upregulation of Akt1, rendering the cancer cells resistant to cisplatin.[108] PI3K/Akt activation and cisplatin resistance also occur in ovarian[109] and bladder[110] cancer.